Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jack Herer is a sativa-dominant hybrid medical cannabis strain developed by Sensi Seeds in the Netherlands during the mid-1990s. It is a genetic cross between a Haze hybrid, Northern Lights #5, and Shiva Skunk. The strain is pharmacologically active as an agonist at the cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), primarily mediated by its delta-9-tetrahydrocannabinol (THC) content, which typically ranges from 15% to 24%. It also contains low levels of cannabidiol (CBD) and a specific terpene profile consisting of terpinolene, caryophyllene, and pinene. Jack Herer is recognized for producing balanced cerebral and physical effects, often described as blissful and creative, and has been distributed as a medical-grade product through Dutch pharmacies. Clinical research has explored its use in various settings, including its potential to improve oxygenation in patients following heart surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jack Herer.